OM DENNE EPISODE
This episode’s Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow’ Sustainability Campaign, and how you can get involved: CLICK HERE
Episode Overview:
Stress is the missing vital sign that determines whether treatments succeed or fail.
Our next guest, Dr. Andrew Holman, is tackling this challenge as CEO of Inmedix. With 25 years of clinical experience as a practicing rheumatologist, Andrew possesses a unique perspective bridging medicine and diagnostics innovation.
Watching billions wasted annually on autoimmune treatments that fail, he developed the CloudHRV platform to measure stress biology with medical-grade precision in just five minutes.
Driven by a passion to end the trial-and-error cycle plaguing chronic disease care, Andrew shares how Inmedix tripled remission rates in rheumatoid arthritis patients from 25% to 79%.
Join us to discover how stress biology is transforming precision medicine and unlocking new outcomes for the 15 million Americans living with autoimmune diseases. Let's go!
Episode Highlights:
- FOUNDER WISDOM: Surround yourself with smarter people who tell you straight where your strengths and weaknesses are.
- ORIGIN STORY: A $10 million patent sale at age 46 came from championing fibromyalgia patients when they were dismissed by medicine.
- CLINICAL BREAKTHROUGH: The FDA-cleared CloudHRV platform tripled remission rates from 25% to 79% by measuring stress biology.
- FUTURE OF MEDICINE: Autonomic nervous system science may be to this century what antibiotics were to the last.
- PASSIONATE PIONEER MOMENT: "I try to be a learn-it-all instead of a know-it-all."
About our Guest:
Dr. Andrew Holman is the CEO of Inmedix. He is a practicing rheumatologist with 25 years of clinical experience who discovered the missing link in healthcare: stress—the unmeasured vital sign that determines whether treatments work or fail.
As a physician watching 75% of autoimmune treatments fail while $10 billion is wasted annually on ineffective drugs, he developed Inmedix's FDA-cleared CloudHRV platform to measure stress biology with medical-grade precision in just 5 minutes. His clinical trials tripled remission rates in rheumatology from 25% to 79%, transforming medicine from trial-and-error to precision care in a $3.1 billion market.
Dr. Holman brings proven commercial execution alongside clinical expertise: he leads a team with decades of experience scaling diagnostics companies through IPOs and acquisitions at Myriad Genetics, Crescendo Bioscience, and Exagen.
Links Supporting This Episode:
- Inmedix Website: CLICK HERE
- Dr. Andrew Holman LinkedIn page: CLICK HERE
- Mike Biselli LinkedIn page: CLICK HERE
- Mike Biselli Twitter page: CLICK HERE
- Visit our website: CLICK HERE
- Subscribe to newsletter: CLICK HERE
- Guest nomination form: CLICK HEREE
- Guest nomination form: CLICK HERE
